Rigel shareholders approve reverse stock split (1:2–1:20) and 6.5M share increase for equity plan

RIGEL PHARMACEUTICALS INC

Reverse stock split of common stock at ratio between 1:2 and 1:20 approved; 87.85M for, 42.50M against.
Amended 2018 Equity Incentive Plan authorized additional 6.5M shares; 53.15M for, 48.24M against.
Two directors elected: Brian L. Kotzin (78.45M for) and Gregg A. Lapointe (79.15M for) to terms until 2027.
Advisory say-on-pay approved (74.74M for, 26.22M against); Ernst & Young ratified as auditor for FY2024.
Adjournment proposal passed (83.11M for) to allow further solicitation if needed for reverse split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.